Tumor loss-of-function mutations in STK11/LKB1 induce cachexia

Puneeth Iyengar, Aakash Y. Gandhi, Jorge Z. Granados, Tong Guo, Arun Gupta, Jinhai Yu, Ernesto M. Llano, Faya Zhang, Ang Gao, Asha Kandathil, Dorothy L. Williams, Boning Gao, Luc Girard, Venkat S. Malladi, John M. Shelton, Bret M. Evers, Raquibul Hannan, Chul Ahn, John D. Minna, Rodney E. InfanteJCI 2023 · DOI

TL;DR

This study identifies mutations in the STK11/LKB1 gene within tumors as a key driver of cancer cachexia, a severe wasting syndrome. The findings suggest that loss-of-function mutations in STK11/LKB1 not only induce cachexia but also serve as a potential biomarker for predicting its development in cancer patients, particularly those with non-small cell lung cancer (NSCLC).

What Problem Does This Paper Address?

Cancer cachexia (CC) is a debilitating condition affecting up to 50% of cancer patients, characterized by significant loss of muscle and adipose tissue, leading to weight loss, reduced quality of life, and increased mortality. Despite its prevalence and severe impact, effective treatments and reliable biomarkers for CC are lacking. This deficiency hinders early diagnosis, patient enrollment in clinical trials, and the development of targeted therapies. The authors aim to identify molecular drivers of CC and potential biomarkers by screening a large panel of cancer cell lines.

Methods

The researchers employed a multi-pronged approach:

  • In Vivo Cachexia Screen: They injected 54 human non-small cell lung cancer (NSCLC) cell lines into immunodeficient mice to observe which lines induced a cachexia phenotype (significant loss of fat and lean mass).
  • Whole-Exome Sequencing (WES): WES was performed on the NSCLC lines to identify genetic alterations associated with cachexia induction.
  • CRISPR/Cas9 Gene Editing: To confirm the role of identified genes, STK11/LKB1 was silenced using CRISPR/Cas9 in NSCLC and murine colorectal carcinoma (CRC) cell lines.
  • Isogenic Model Generation: This gene editing allowed for the creation of isogenic cell line pairs (wild-type vs. STK11/LKB1-silenced) to isolate the effect of STK11/LKB1 loss.
  • Tumor Microenvironment Analysis: Techniques like flow cytometry and quantitative PCR were used to assess changes in immune cell composition and cytokine expression within the tumor microenvironment of mice bearing STK11/LKB1-mutant tumors.
  • Circulating Tumor DNA (ctDNA) Analysis: A cohort of NSCLC patients had their ctDNA analyzed to correlate STK11/LKB1 mutations with the presence of weight loss at cancer diagnosis.
  • Immunoblotting: Used to assess protein expression levels of STK11/LKB1 and its downstream targets.

Datasets

  • Human NSCLC Cell Lines: 54 human NSCLC cell lines were used for the initial in vivo cachexia screen.
  • Murine Colorectal Carcinoma (CRC) Cell Lines: Used for validation of STK11/LKB1's role in a different cancer type and host background.
  • COSMIC Cell Line Encyclopedia: Utilized for whole-exome sequencing data of NSCLC lines.
  • Clinical Patient Cohort: ctDNA data from 246 NSCLC patients was analyzed. This dataset was collected as part of an IRB-approved protocol and included variant analysis of 74 genes, including STK11/LKB1. Patient weight loss data was retrospectively collected from electronic medical records and physician/provider notes.

Key Insights and Ideas

  • STK11/LKB1 as a Cachexia Driver: The most striking finding is the strong correlation between loss-of-function mutations in STK11/LKB1 and the induction of cancer cachexia. This suggests a direct causal link, not just an association.
  • Tumor-Intrinsic Mechanism: The study demonstrates that the tumor itself, through STK11/LKB1 mutations, can initiate the cachexia process, independent of tumor size or food intake differences.
  • Immune Microenvironment Modulation: STK11/LKB1 loss in tumors alters the tumor microenvironment, leading to changes in immune cell populations and increased pro-inflammatory cytokines, which likely contribute to host wasting.
  • Biomarker Potential: The high concordance (89%) between STK11/LKB1 mutations in patient ctDNA and weight loss at diagnosis positions STK11/LKB1 as a promising genetic biomarker for predicting cachexia risk.
  • Cross-Cancer Relevance: The findings were validated in both NSCLC and murine CRC models, suggesting that STK11/LKB1's role in cachexia may extend beyond NSCLC.

Key Results

  • Out of 54 NSCLC lines screened, 17 induced a clear cachexia phenotype.
  • Whole-exome sequencing revealed that 80% of cachexia-inducing NSCLC lines (8 out of 10) harbored STK11/LKB1 mutations, while none of the non-cachexia lines did.
  • Silencing STK11/LKB1 in a non-cachexia-inducing NSCLC line (H1792) converted it into a cachexia-inducing line, causing significant fat and lean mass loss in mice.
  • STK11/LKB1-mutant tumors showed altered immune cell infiltration (decreased monocytes, macrophages, dendritic cells) and increased pro-inflammatory cytokine mRNA and serum levels (e.g., IL-6, LIF).
  • In a cohort of 246 NSCLC patients, 89% of those with STK11/LKB1 mutations also exhibited weight loss at cancer diagnosis.
  • Patients with STK11/LKB1 variants had significantly reduced overall survival compared to those with wild-type STK11/LKB1, especially when combined with weight loss.

Limitations and Future Work

  • Mouse Models: While valuable, mouse models may not perfectly recapitulate human disease complexity. The authors acknowledge the need for further validation in more diverse human cohorts.
  • Mechanism of Action: While the study implicates STK11/LKB1 in modulating the immune microenvironment and cytokine production, the precise downstream molecular pathways linking STK11/LKB1 loss to specific immune cell changes and cytokine signaling require further detailed investigation using single-cell techniques.
  • Other Genes: While STK11/LKB1 is a strong candidate, the authors note that other genetic alterations might also contribute to cachexia development, as suggested by the 20% of cachectic patients with STK11/LKB1 variants not having the mutation.
  • Therapeutic Strategies: The study suggests that targeting the tumor microenvironment or downstream pathways of STK11/LKB1 (e.g., JAK inhibitors) could be therapeutic avenues. They are currently conducting a clinical trial evaluating JAK inhibition in combination with standard-of-care treatments for advanced NSCLC.
  • Broader Cancer Types: The authors propose extending this research to other cancer types known to be associated with STK11/LKB1 alterations and cachexia to identify potentially novel tumor-intrinsic genetic drivers of wasting.

Summary updated

Abstract

Cancer cachexia (CC), a wasting syndrome of muscle and adipose tissue resulting in weight loss, is observed in 50% of patients with solid tumors. Management of CC is limited by the absence of biomarkers and knowledge of molecules that drive its phenotype. To identify such molecules, we injected 54 human non-small cell lung cancer (NSCLC) lines into immunodeficient mice, 17 of which produced an unambiguous phenotype of cachexia or non-cachexia. Whole-exome sequencing revealed that 8 of 10 cachexia lines, but none of the non-cachexia lines, possessed mutations in serine/threonine kinase 11 (STK11/LKB1), a regulator of nutrient sensor AMPK. Silencing of STK11/LKB1 in human NSCLC and murine colorectal carcinoma lines conferred a cachexia phenotype after cell transplantation into immunodeficient (human NSCLC) and immunocompetent (murine colorectal carcinoma) models. This host wasting was associated with an alteration in the immune cell repertoire of the tumor microenvironments that led to increases in local mRNA expression and serum levels of CC-associated cytokines. Mutational analysis of circulating tumor DNA from patients with NSCLC identified 89% concordance between STK11/LKB1 mutations and weight loss at cancer diagnosis. The current data provide evidence that tumor STK11/LKB1 loss of function is a driver of CC, simultaneously serving as a genetic biomarker for this wasting syndrome.
BibTeX
@inproceedings{iyengar2023tumor,
  author = {Puneeth Iyengar and Aakash Y. Gandhi and Jorge Z. Granados and Tong Guo and Arun Gupta and Jinhai Yu and Ernesto M. Llano and Faya Zhang and Ang Gao and Asha Kandathil and Dorothy L. Williams and Boning Gao and Luc Girard and Venkat S. Malladi and John M. Shelton and Bret M. Evers and Raquibul Hannan and Chul Ahn and John D. Minna and Rodney E. Infante},
  title = {{Tumor loss-of-function mutations in STK11/LKB1 induce cachexia}},
  booktitle = {JCI},
  year = {2023},
  doi = {10.1172/jci.insight.165419},
}
Figure